How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Sell
34
MRUS Quote, Financials, Valuation and Earnings
Last price:
$42.23
Seasonality move
:
9.76%
Day range:
$39.00 - $45.44
52-week range:
$37.77 - $61.61
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
79.27x
P/B ratio:
4.76x
Volume:
396.5K
Avg. volume:
679.9K
1-year change:
-0.93%
Market cap:
$3.1B
Revenue:
$36.1M
EPS (TTM):
-$3.27
Analysts' Opinion
-
Consensus RatingMerus NV has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $87.20, Merus NV has an estimated upside of 95.47% from its current price of $44.61.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $67.00 representing -50.19% downside risk from its current price of $44.61.
Fair Value
-
According to the consensus of 13 analysts, Merus NV has 95.47% upside to fair value with a price target of $87.20 per share.
MRUS vs. S&P 500
-
Over the past 5 trading days, Merus NV has underperformed the S&P 500 by -4.1% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Merus NV does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Merus NV has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Merus NV reported revenues of $9.1M.
Earnings Growth
-
Merus NV has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Merus NV reported earnings per share of -$0.41.
Enterprise value:
2.5B
EV / Invested capital:
--
Price / LTM sales:
79.27x
EV / EBIT:
--
EV / Revenue:
70.44x
PEG ratio (5yr expected):
-1.80x
EV / Free cash flow:
-13.56x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-31%
Net Income Margin (TTM):
-595.93%
Return On Equity:
-38.4%
Return On Invested Capital:
-38.4%
Operating Margin:
-969.93%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $41.6M | $43.9M | $36.1M | $8.9M | $9.1M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$160M | -$156.5M | -$272.1M | -$47.5M | -$88.7M | |
| EBITDA | -$158.8M | -$154M | -$269.6M | -$46.9M | -$88.1M | |
| Diluted EPS | -$2.90 | -$3.04 | -$3.27 | -$1.09 | -$0.41 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $218M | $424.2M | $306.4M | $368.8M | $569.1M | |
| Total Assets | $231.2M | $456.6M | $376.5M | $455.5M | $782.7M | |
| Current Liabilities | $46.7M | $71.9M | $78.9M | $69.1M | $87.1M | |
| Total Liabilities | $129M | $140.4M | $129.5M | $99.2M | $134.8M | |
| Total Equity | $102.3M | $316.2M | $247.1M | $356.3M | $647.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$149.9M | -$142.2M | -$185.8M | -$36.3M | -$66.7M | |
| Cash From Investing | $2.8M | -$27M | -$220.2M | -$2.1M | -$77.7M | |
| Cash From Financing | $58.7M | $230.1M | $494M | $1.5M | $8.1M | |
| Free Cash Flow | -$157.5M | -$146.2M | -$187.7M | -$36.3M | -$66.7M | |
MRUS
Sector
Market Cap
$3.1B
$36.4M
Price % of 52-Week High
72.41%
44.07%
Dividend Yield
0%
0%
Shareholder Yield
-15.81%
-1.03%
1-Year Price Total Return
-0.93%
-41.85%
Beta (5-Year)
1.151
0.775
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$46.52
200-day SMA
Sell
Level
$48.70
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$46.65
Relative Strength Index (RSI14)
Sell
Level
38.04
ADX Line
Neutral
Level
0
Williams %R
Buy
Level
-89.6259
50-day SMA
Sell
Level
$43.67
MACD (12, 26)
Buy
Level
0.42
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (10.7916)
Sell
CA Score
(Annual)
Level (-0.9958)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (1.3774)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Stock Forecast FAQ
In the current month, MRUS has received 13 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MRUS average analyst price target in the past 3 months is $87.20.
-
Where Will Merus NV Stock Be In 1 Year?
According to analysts, the consensus estimate is that Merus NV share price will rise to $87.20 per share over the next 12 months.
-
What Do Analysts Say About Merus NV?
Analysts are divided on their view about Merus NV share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Merus NV is a Sell and believe this share price will drop from its current level to $67.00.
-
What Is Merus NV's Price Target?
The price target for Merus NV over the next 1-year time period is forecast to be $87.20 according to 13 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MRUS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Merus NV is a Buy. 13 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MRUS?
You can purchase shares of Merus NV via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Merus NV shares.
-
What Is The Merus NV Share Price Today?
Merus NV was last trading at $42.23 per share. This represents the most recent stock quote for Merus NV. Yesterday, Merus NV closed at $44.61 per share.
-
How To Buy Merus NV Stock Online?
In order to purchase Merus NV stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Raymond James Stock a Buy, Sell or Hold?
Raymond James Financial (NYSE:RJF) is one of America’s large financial…
Is JHX Stock a Buy Sell or Hold?
James Hardie Industries (NYSE:JHX) is a manufacturer of outside building…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
69
AJINY alert for Apr 1
Ajinomoto [AJINY] is down 2.15% over the past day.
Sell
40
RGC alert for Mar 31
Regencell Bioscience Holdings [RGC] is up 26.1% over the past day.
Buy
62
AGX alert for Apr 1
Argan [AGX] is down 4.98% over the past day.
